XellSmart reports Phase I Parkinson’s cell therapy data
New clinical data for XellSmart’s off-the-shelf cell therapy XS411 were presented at the International Congress of Parkinson’s Disease and Movement Disorders on 18 Oct. 2026. The Phase I single-arm, open-label dose‑escalation study enrolled nine participants with moderate-to-advanced Par
<p>New clinical data for XellSmart’s off-the-shelf cell therapy XS411 were presented at the International Congress of Parkinson’s Disease and Movement Disorders on 18 Oct. 2026. The Phase I single-arm, open-label dose‑escalation study enrolled nine participants with moderate-to-advanced Par</p>